Novozymes measures the success of its R&D investments using an internal rate of return (IRR) model. The model calculates the IRR of new product and concept sales based on a lifecycle model for each of Novozymes' industry subgroups. The IRR is then compared to the company's weighted average cost of capital (WACC) - investments with an IRR above the WACC are continued, while those below are avoided. On average from 2007-2011, Novozymes' IRR was 21.1% compared to a WACC of 15%, indicating its R&D investments have been successful.